• 1
    Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am. J. Manag. Care 2000; 6 (Suppl): S58090.
  • 2
    Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999; 83: 58390.
  • 3
    Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003; 20: 32736.
  • 4
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87: 7606.
  • 5
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 3749.
  • 6
    Homma Y, Yamaguchi O, Hayashi K; Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005; 96: 13148.
  • 7
    Kobayashi F, Yageta Y, Segawa M, Matsuzawa S. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 2007; 57: 92100.
  • 8
    Kobayashi F, Yageta Y, Yamazaki T et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 2007; 57: 14754.
  • 9
    Murakami S, Yoshida M, Iwashita H et al. Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int. 2003; 71: 2908.
  • 10
    Homma Y, Gotoh M, Ando T, Fukuhara S. Development of Japanese version of QOL questionnaires for urinary incontinence. J. Neurogenic Bladder Soc. 1999; 10: 22536.
  • 11
    The ICH Steering Committee. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. ICH harmonized tripartite guideline. Step 4 of the ICH process. 1994.
  • 12
    Yamaguchi O. Pathophysiology of the overactive bladder and its pharmacological treatment. Folia Pharmacol Jpn. 2003; 121: 3318.
  • 13
    Takei M, Homma Y; The Japanese Tolterodine Study Group. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int. J. Urol. 2005; 12: 45664.
  • 14
    Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur. Urol. 2002; 41: 58895.
  • 15
    Yamaguchi O. Long-term safety and efficacy of solifenacin succinate in patients with overactive bladder. Jpn. Pharmacol. Ther. 2006; 34 (Suppl): S6986.
  • 16
    Haab F, Cardozo L, Chapple C, Ridder AM for the Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. 2005; 47: 37684.
  • 17
    Roden DM. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 2004; 350: 101322.
  • 18
    Andersson KE. Anti-muscarinics for treatment of overactive bladder. Lancet Neurol. 2004; 3: 4653.